If you have been reading about certificate of analysis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
I may, however, remark that when the temperature of the ether is only a little above its boiling point, its condensation is a little more rapid than that of atmospheric air. This fact is related to a phenomenon which is exhibited by a great many bodies when passing from the liquid to the solid-state, but which is no longer sensible at temperatures a few degrees above that at which the transition occurs.
In the chemical industry, carbon dioxide is mainly consumed as an ingredient in the production of urea, with a smaller fraction being used to produce methanol and a range of other products. Some carboxylic acid derivatives such as sodium salicylate are prepared using CO2 by the Kolbe–Schmitt reaction. Captured CO2 could be to produce methanol or electrofuels. To be carbon-neutral, the CO2 would need to come from bioenergy production or direct air capture.
Monitoring a person's health over time after treatment. This includes keeping track of the health of people who participate in a clinical study or clinical trial for a period of time, both during the study and after the study ends. (NCI) Food and Drug Administration (FDA)
== Taxonomy == The genus Glycine may be divided into two subgenera, Glycine and Soja. The subgenus Soja includes the cultivated soybean, G.max, and the wild soybean, treated either as a separate species G.soja, or as the subspecies G.max subsp. soja. The cultivated and wild soybeans are annuals. The wild soybean is native to China, Japan, Korea and Russia. The subgenus Glycine consists of at least 25 wild perennial species: for example, G. canescens and G. tomentella, both found in Australia and Papua New Guinea. Perennial soybean (Neonotonia wightii) belongs to a different genus. It originated in Africa and is now a widespread pasture crop in the tropics. Like some other crops of long domestication, the relationship of the modern soybean to wild-growing species can no longer be traced with any degree of certainty. It is a cultigen with a very large number of cultivars.
I'd say I can't really tell you much other than that there are zero plans to tour again. As I said earlier, we're very close and talk all the time, but we don't talk about work. We're friends, and we talk about life as friends. I can't really tell you more than that, I'm afraid. I would say there's no chance of seeing Rush on tour again as Alex, Geddy, Neil. But would you see one of us or two of us or three of us? That's possible. On January 7, 2020, Peart died at the age of 67 after a 3½-year battle with glioblastoma, a type of brain cancer. In 2021, Lee confirmed to Rolling Stone that Rush was "over" and expressed the impossibility of the band continuing without Peart: "That's finished, right? That's over. I still am very proud of what we did. I don't know what I will do again in music... I'm sure Al doesn't, whether its together, apart, or whatever. But the music of Rush is always part of us... I would never hesitate to play one of those songs in the right context. But at the same time, you have to give respect to what the three of us with Neil did together."
Sources: en.wikipedia.org
=== Notable members === Ebenezer Allen – militia member (lieutenant) (Ethan Allen's cousin) Ethan Allen – militia leader (general) Ira Allen – militia leader, and the founder of the University of Vermont (Ethan Allen's brother) Remember Baker – militia member (captain) (Ethan Allen's cousin) John Fassett Jr. – Vermont Supreme Court Justice, 1778–1786, diarist who chronicled the Green Mountain Boys' 1775 expedition to Canada. David Fay – Vermont Supreme Court Justice, adjutant general of the Vermont Militia Jonas Fay – regimental surgeon and political leader of early Vermont Jonas Galusha – militia leader (captain), future governor of Vermont Joab Hoisington – militia leader, Hoisington's Rangers (major), served in the French-Indian War, and participated in the Battle for Crown Point Matthew Lyon – militia member (second lieutenant), and future congressman David Robinson – son of Captain Samuel Robinson, a founder of Bennington Moses Robinson – colonel in Vermont Militia during American Revolution, 2nd governor of Vermont Republic, one of the first two senators from Vermont. Thomas Rowley – poet, militia member, and spokesman, known as the "Bard of the Green Mountains" who "Set the Hills on Fire". Elishama Tozer – militia member (lieutenant) Seth Warner – militia leader (colonel)
== Chestnut family colors == Chestnut is considered a "base color" in the discussion of equine coat color genetics. Additional coat colors based on chestnut are often described in terms of their relationship to chestnut:
The scenario of a large unification of civilizations over an extent of 1 to 10 billion light-years with concentration in a certain region has a probability of 60%. These civilizations are to be searched for in the most powerful quasars and in the galactic bulge, at a radiation level higher than 1038 W, in the wavelengths from 10 μm to 10 cm, as well as in the other regions of the spectrum. This is to detect megastructures or signals with a wavelength of 1.5 mm and omnidirectional emission up to 21 cm. In the event of contact, humanity would see progress in all areas of society in order to join this supercivilization; it is also expected that an ethnographic conservatory would be created on Earth. The scenario of a unification on the scale of the galactic cluster has only a 20% probability of realization. Kardashev advises to observe the Virgo cluster (especially M87) and other clusters in a similar way as in the first scenario. The consequences for humanity are the same as in the first scenario. The scenario of a unification on the scale of galaxies has only a 10% probability. To confirm it, we must study the galactic centers, both of the Milky Way and of neighboring galaxies (such as M31, M33), according to a procedure similar to that of the first scenario. The consequences for humanity are the same as in the first scenario. The scenario of a complete colonization of space has no probability of being realized according to Kardashev because if it were realizable then "they" would already be on Earth; yet this is not the case.
== Prevalence == While the heritability of hypermobility is strong, specific genes implicated in the condition have not been identified. Prevalence of HSD alone is unknown, though previous estimates have placed the combined prevalence of hEDS and HSD between 194.2 per 100 000 (0.19%) or 1 in 500 people. Other studies have suggested that it affects around 3% of the UK population. The condition is relatively common in those attending musculoskeletal clinics.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.